Eribulin Mesylate API Manufacturer & Supplier in India

Swapnroop Pharma · WHO-GMP Certified · +91 87670 62101

Eribulin Mesylate API Manufacturer & Supplier in India

Eribulin Mesylate is a synthetic analogue of halichondrin B and an antineoplastic active pharmaceutical ingredient (API). It is a microtubule dynamics inhibitor that binds to tubulin and suppresses microtubule growth, resulting in inhibition of cancer-cell proliferation.

Eribulin Mesylate is the mesylate salt of eribulin and is used in pharmaceutical formulations for the treatment of certain advanced or metastatic cancers.

What is Eribulin Mesylate?

Eribulin Mesylate is a synthetic small-molecule anticancer drug substance. It is structurally related to the natural marine-product compound halichondrin B and retains the pharmacologically active portion of that molecule.

The molecular formula of Eribulin Mesylate is C₄₀H₅₉NO₁₁·CH₄O₃S, and its molecular weight is approximately 826.00 g/mol. The CAS Registry Number is 441045-96-5.

Mechanism of Action

Eribulin binds to tubulin and inhibits microtubule polymerization. Unlike taxanes, which primarily stabilize microtubules, eribulin suppresses microtubule growth without affecting depolymerization.

This results in:

  • Suppression of microtubule growth
  • Disruption of mitotic spindle formation
  • Prolonged mitotic blockage
  • Inhibition of cancer-cell proliferation
  • Induction of apoptosis following prolonged mitotic arrest

Pharmaceutical Applications

Eribulin Mesylate is primarily associated with:

  • Metastatic breast cancer
  • Unresectable or metastatic liposarcoma
  • Antineoplastic pharmaceutical formulations
  • Oncology drug development
  • Cancer-treatment research

The FDA-approved product HALAVEN (eribulin mesylate) is indicated for specific patients with metastatic breast cancer and unresectable or metastatic liposarcoma.

Eribulin Mesylate API

Eribulin Mesylate is a synthetic small-molecule oncology API. Pharmaceutical-grade material requires appropriate control of identity, assay, related substances, water content, residual solvents and other applicable quality attributes.

Because Eribulin Mesylate is a complex synthetic molecule, its impurity profile and stereochemical integrity are particularly important during pharmaceutical manufacturing and quality control.

Quality & Regulatory Considerations

Eribulin Mesylate API intended for pharmaceutical manufacturing should comply with the applicable approved specification and relevant regulatory requirements.

Typical quality-control parameters may include:

  • Identification
  • Assay
  • Related substances
  • Water content
  • Residual solvents
  • Elemental impurities
  • Optical rotation, where applicable
  • Specific impurity controls
  • Microbial quality, where applicable

A qualified supplier should provide appropriate Certificate of Analysis (CoA), specification sheet, SDS/MSDS, batch traceability and applicable regulatory documentation.

Storage

Eribulin Mesylate should be stored in a tightly closed container, protected from moisture, light and excessive heat, according to the approved specification and stability requirements.

Detailed Specifications

Parameter Specification
Appearance White to off-white crystalline powder
Identification IR & HPLC compliant
Assay (HPLC) 98.0% – 102.0%
Loss on Drying NMT 2.0%
Residue on Ignition NMT 0.5%
Heavy Metals NMT 20 ppm
pH (1% Solution) 2.0 – 4.0
Individual Impurity NMT 0.5%
Total Impurities NMT 1.0%
Water Content NMT 1.0%
Melting Point 150°C – 154°C
Get Bulk Quote via WhatsApp